Healthcare / BiotechnologyNasdaqCM
$2.56
-0.17 (-6.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-45.9M · quality 59.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$478M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-13.3%
↓Gross Margin
N/A
•Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2015–2025 · 10 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-528.6%
FCF / Net income
2.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.3M · net income $-17.4M · FCF $-38.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | $7.3M | $7.3M | $566000.00 | $392000.00 | $1.5M | $208.4M | — | — | — | — | — | — |
| Net Income | $-17.4M | $-17.4M | $-26.4M | $-52.3M | $-54.2M | $122.8M | $-81.0M | $-60.5M | $-52.0M | $-64.8M | $-22.4M | $-13.2M |
| EBITDA | $-42.2M | $-42.2M | $-61.3M | $-58.7M | $-54.2M | $124.4M | $-81.1M | $-61.2M | $-52.8M | $-64.9M | $-22.5M | $-13.2M |
| EPS | -0.23 | -0.23 | -0.37 | -0.73 | -0.77 | 1.76 | -1.39 | — | — | — | — | — |
| Operating Margin | -585.2% | -585.2% | -10933.7% | -15122.7% | -3696.4% | 59.6% | — | — | — | — | — | — |
| Net Margin | -240.1% | -240.1% | -4670.1% | -13351.8% | -3604.7% | 58.9% | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||
| Debt/Equity | 0.10 | 0.10 | 0.22 | 0.18 | 0.13 | — | — | — | — | — | — | — |
| Current Ratio | 10.17 | 10.17 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $-38.3M | $-38.3M | $-56.1M | $-45.9M | $-56.6M | $118.4M | $-51.7M | $-51.1M | $-45.6M | $-31.5M | — | — |
| Returns | ||||||||||||
| ROE | -13.3% | -13.3% | -38.7% | -59.6% | -41.0% | 68.3% | -185.7% | -86.3% | -134.0% | -77.7% | -45.5% | -19.3% |
| Valuation | ||||||||||||
| P/B | 1.44 | 1.44 | 1.00 | 2.45 | 1.00 | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||
| Revenue Growth | 1181.3% | 1181.3% | 44.4% | -73.9% | — | — | — | — | — | — | — | — |
| EPS Growth | 37.8% | 37.8% | 49.3% | 5.2% | — | 226.6% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+841.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.37 → -0.23
Residual
+841.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.